Company / Revenue
NEKTAR THERAPEUTICS Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$55.2M
FY2025
5-year range
$55.2M / $101.9M
FY2021-FY2025
Trend
-38.7%
vs FY2024
Sector context
#118 of 155
Health Care
What the data says
NEKTAR THERAPEUTICS's revenue of $55M is lower than 76% of companies in the Health Care sector (FY2025). Revenue has fluctuated over the past 10 years, ranging from $25M in FY2017 to $1.2B in FY2020.
Based on SEC 10-K filings.
$55M in FY2025 with a 5-year CAGR of -45.9%.
Declined from $102M to $55M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -15.7%
- 5-Year CAGR
- -45.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 155This company $55.2M Sector average $4.5B
▼
-98.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -45.9%, indicating a declining trend.
- In FY2025, revenue decreased 38.7% year-over-year.
- Ranks #118 out of 155 companies in the Health Care sector.
- Peak revenue was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $55.2M | -38.7% |
| FY2024 | $90.1M | -11.6% |
| FY2023 | $101.9M | +10.7% |
| FY2022 | $92.1M | -9.7% |
| FY2021 | $101.9M | -91.5% |
| FY2020 | $1.2B | +287.8% |
| FY2019 | $307.7M | +86.0% |
| FY2018 | $165.4M | +569.0% |
| FY2017 | $24.7M | -87.7% |
| FY2016 | $200.7M | -13.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026